-
The Power of Team-Based Science
After being awarded the $2.5 million IASLC-LCRF grant, ILCN follows up with the research progress of Dr. David Barbie and his international team of investigators.
More Recent News
-
Targeting NRG1 Fusions: A Potential Role for Zenocutuzumab as a First-Line Therapeutic Option
Dr. Stephen Liu recently highlighted the safety and efficacy of a targeted therapy for patients with NRG1-positive cancers with updated data from the ongoing eNRGy trial.
-
Lung Cancer is Treatable When Found Early. So Why Don’t We Screen Everyone?
Advocate and survivor Jan Pezarro details how investing in a universal age-based lung cancer screening model can save both lives and health care costs.